Published Date:2022-08-23 Original Link:https://www.onenessbio.com/en/news_detail175_2.htm No 1 Date of announcement 2022/08/23 Time of announcement  22:58:56 Subject Oneness submitted an IND to US FDA for a phase I clinical trial on the broad-spectrum anti-SARS-CoV-2 siRNA (SNS812) co-developed with Microbio (Shanghai) To which item it meets paragraph 10 Date of events 2022/08/23 Statement Product:SNS812, a broad-spectrum siRNA against...Read More